Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma and Low Peripheral Blood CD34+ Cell Count: Results of a Subset Analysis of a Randomized Trial

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 10, 2012, Pages 1564-1572

  Nademanee, Auayporn P ^a   DiPersio, John F ^b   Maziarz, Richard T ^c   Stadtmauer, Edward A ^d   Micallef, Ivana N ^e   Stiff, Patrick J ^f   Hsu, Frank J ^g   Bridger, Gary ^g   Bolwell, Brian J ^h  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MAYO CLINIC   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g GENZYME CORPORATION   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

AMD 3100; Poor mobilzer; Stem cell mobilization

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLERIXAFOR;

ADULT; AGED; APHERESIS; ARTICLE; BLOOD CELL COUNT; CD34 SELECTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENGRAFTMENT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NEUTROPHIL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STEM CELL MOBILIZATION; THROMBOCYTE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLACEBOS; RECEPTORS, CXCR4; TRANSPLANTATION, AUTOLOGOUS;

EID: 84866169152     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.05.017     Document Type: Article

References (25)

1. + cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion 2003, 43:622-625.
2. Hill Q.A., Buxton D., Pearce R., et al. An analysis of the optimal timing of peripheral blood stem cell harvesting following priming with cyclophosphamide and G-CSF. Bone Marrow Transplant 2007, 40:925-930.
3. Basquiera A.L., Abichain P., Damonte J.C., et al. The number of CD34(+) cells in peripheral blood as a predictor of the CD34(+) yield in patients going to autologous stem cell transplantation. J Clin Apher 2006, 21:92-95.
4. Armitage S., Hargreaves R., Samson D., et al. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant 1997, 20:587-591.
5. Meehan K.R., Hill J.M., Patchett L., et al. Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization. Transfusion 2006, 46:523-529.
6. + cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998, 38:385-391.
7. + cells as the best predictor of peripheral hematopoietic stem cell yield. J Hematother 1999, 8:255-262.
8. Pusic I., Jiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
9. Wuchter P., Ran D., Bruckner T., et al. Poor mobilization of hematopoietic stem cells: definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010, 16:490-499.
10. Matthys P., Hatse S., Vermeire K., et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-γ receptor-deficient mice. J Immunol 2001, 167:4686-4692.
11. Hatse S., Princen K., Bridger G., et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527:255-262.
12. + hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45:295-300.
13. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
14. Mozobil [package insert]. Cambridge, MA: Genzyme Corporation; 2010.
15. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
16. + cells compared to placebo plus G-CSF: results from two randomized, placebo-controlled trials in patients with multiple myeloma or non-Hodgkin's lymphoma [abstract]. Blood 2009, 114. abstr 3224.
17. + cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999, 12:1227-1233.
18. Weaver C.H., Hazelton B., Birch R., et al. Analysis of engraftment kinetics as a function of CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995, 86:3961-3969.
19. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003, 349:2495-2502.
20. Barlogie B., Attal M., Crowley J., et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 2010, 28:1209-1214.
21. Fermand J.P., Ravaud P., Chevret S., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92:3131-3136.
22. Kumar S., Giralt S., Stadtmauer E.A., et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009, 114:1729-1735.
23. Giralt S., Stadtmauer E.A., Harousseau J.L., et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009, 23:1904-1912.
24. Shaughnessy P., Islas-Ohlmayer M., Murphy J., et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011, 17:729-736.
25. Costa L.J., Alexander E.T., Hogan K.R., et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011, 46:64-69.